Mochida Pharmaceutical achieved sales of JPY 116.9 billion (up 11.2%) and net income of JPY 7.9 billion (up 39%) for the fiscal year ending March 2026. The pharmaceutical and healthcare businesses performed well, with sales forecasts of JPY 126.0 billion and net income of JPY 10.0 billion in 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4534-20260515-01.pdf","jir_short_summary":"Mochida Pharmaceutical achieved sales of JPY 116.9 billion (up 11.2%) and net income of JPY 7.9 billion (up 39%) for the fiscal year ending March 2026. The pharmaceutical and healthcare businesses performed well, with sales forecasts of JPY 126.0 billion and net income of JPY 10.0 billion in 2027.","jir_summary":"### Performance Overview\nMochida Pharmaceutical achieved sales of JPY 116.9 billion (up 11.2% YoY) and net income of JPY 7.9 billion (up 39%) for the fiscal year ending March 2026. The pharmaceutical business maintained growth driven by the expansion of new drugs and the impact of drug price revisions. The healthcare segment also performed well, with R&D expenses totaling JPY 12.157 billion, continuing proactive investments. For 2027, sales are forecasted at JPY 126.0 billion and net income at JPY 10.0 billion, projecting growth.\n\n### Future Outlook and Shareholder Returns\nMochida Pharmaceutical anticipates sales of JPY 126.0 billion (up 7.7%) and net income of JPY 10.0 billion (up 26.5%) for the fiscal year ending March 2027, accelerating efforts to penetrate existing drug markets and develop new drugs. The company plans to distribute an annual dividend of JPY 85 and actively enhance shareholder returns. Additionally, it is promoting R&D and overseas partnerships as part of its long-term growth strategy.","jir_financial_highlights":"Sales: 116,951\u767e\u4e07\u5186 (YoY +11.2%)\nNet income attributable to owners of parent: 7,903\u767e\u4e07\u5186 (YoY +39.0%)\nTotal assets: 182,720\u767e\u4e07\u5186 (YoY +22,599\u767e\u4e07\u5186)","jir_category":"","jir_hashtags":"#MochidaPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Sales: JPY 116.9 billion (up 11.2% YoY)\nNet income: JPY 7.9 billion (up 39% YoY)\nTotal assets: JPY 1,827 billion (up 22.6% YoY)","jir_meta_title":"[Mochida Pharmaceutical] Financial Results for 2026 | Sales of JPY 116.9 billion, Net Income of JPY 7.9 billion (up 39% YoY)","jir_meta_description":"Mochida Pharmaceutical achieved sales of JPY 116.9 billion and net income of JPY 7.9 billion for the fiscal year ending March 2026. In 2027, sales are forecasted at JPY 126.0 billion and net income at JPY 10.0 billion, with accelerated R&D and overseas expansion. Shareholder returns are also being strengthened.","jir_og_title":"[Mochida Pharmaceutical] Financial Results for 2026 | Sales of JPY 116.9 billion, Net Income of JPY 7.9 billion","jir_og_description":"Mochida Pharmaceutical achieved sales of JPY 116.9 billion and net income of JPY 7.9 billion for the fiscal year ending March 2026. Sales are projected to reach JPY 126.0 billion and net income JPY 10.0 billion in 2027, as part of its growth strategy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-52170","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n